cbdMD, Inc.

cbdMD, Inc. has successfully completed the acquisition of the operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and ResVitale. This strategic move, finalized through a Florida Chapter 727 assignment for the benefit of creditors, diversifies cbdMD's wellness portfolio beyond hemp-derived products and reduces its reliance on that category. The acquisition brings iconic brands with decades of history in vitamins and nutritional supplements into cbdMD's existing portfolio. The consideration involved assuming senior secured debt, issuing approximately 2.23 million shares of common stock, and a $1.75 million promissory note to Akretive Holdings, LLC.

cbdMD, Inc. reported a net loss of $(1,127,202) for the three months ended June 30, 2026, and $(2,208,315) for the nine months ended June 30, 2026. Despite an increase in net sales to $5,553,738 for the quarter and $16,210,701 for the nine months, the company issued a going concern warning due to continued losses and the need for additional funding. The company also completed an all-stock acquisition of Bluebird Botanicals and saw an increase in cash and cash equivalents.

cbdMD, Inc. entered into a Third Amendment to Lease, extending its warehouse and executive office lease for 62 months until November 30, 2031. The company reduced its leased space from 80,000 to 40,000 square feet, which management believes is sufficient for current and expected operations. This amendment is expected to result in an annual reduction of gross rent expense by approximately $450,000 and net rent expense by $100,000 to $120,000, aligning with the company's long-term needs and reducing operating expenses.

cbdMD reported a net loss of $(1.08) million for the six months ended March 31, 2026, an increase from $(0.47) million in the prior year, despite an 8.05% rise in total net sales to $10.66 million. The company's accumulated deficit reached approximately $180.6 million, leading to a substantial doubt about its ability to continue as a going concern. During the period, cbdMD completed the acquisition of Bluebird Botanicals and issued Series C Preferred Stock.